Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 25, Issue 3, Pages 403-418
Publisher
Springer Nature
Online
2019-03-07
DOI
10.1038/s41591-019-0376-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas
- (2018) W Harb et al. ANNALS OF ONCOLOGY
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
- (2018) Wanqiang Sheng et al. CELL
- Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
- (2018) Horrick Sharma CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
- (2018) Khushboo Agrawal et al. PHARMACOLOGY & THERAPEUTICS
- Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
- (2018) Andrea Kuendgen et al. Oncotarget
- Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing
- (2018) Sarah V. Gerhart et al. Scientific Reports
- MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
- (2018) Anastasia Wyce et al. Oncogenesis
- Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
- (2018) Brianne Cruickshank et al. Frontiers in Immunology
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- Uveal melanoma patients (pts) treated with abbv-075 (mivebresib), a pan-inhibitor of bromodomain and extraterminal (BET) proteins: Results from a phase 1 study.
- (2018) Sapna Pradyuman Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.
- (2018) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.
- (2018) Sarina Anne Piha-Paul et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.
- (2018) Gautam Borthakur et al. JOURNAL OF CLINICAL ONCOLOGY
- 1615PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)
- (2018) M Gounder et al. ANNALS OF ONCOLOGY
- Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L
- (2017) Nigel J. Waters EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
- (2017) F. Morschhauser et al. HEMATOLOGICAL ONCOLOGY
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
- (2017) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- Transcription control by the ENL YEATS domain in acute leukaemia
- (2017) Michael A. Erb et al. NATURE
- ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia
- (2017) Liling Wan et al. NATURE
- Developing Spindlin1 small-molecule inhibitors by using protein microarrays
- (2017) Narkhyun Bae et al. Nature Chemical Biology
- Cancer-Associated Mutations in Endometriosis without Cancer
- (2017) Michael S. Anglesio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing histone demethylase inhibitors in cells: lessons learned
- (2017) Stephanie B. Hatch et al. Epigenetics & Chromatin
- Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
- (2017) Jon S. Zawistowski et al. Cancer Discovery
- Discovery of a PCAF Bromodomain Chemical Probe
- (2016) Moses Moustakim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Identification of potent, selective KDM5 inhibitors
- (2016) Victor S. Gehling et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers
- (2016) Peter J. O’Dwyer et al. CANCER RESEARCH
- Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
- (2016) John P. McGrath et al. CANCER RESEARCH
- Identification and Structure-Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1
- (2016) Dina Robaa et al. ChemMedChem
- Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
- (2016) Maximilian Stahl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dysregulation of TET2 in hematologic malignancies
- (2016) Shigeru Chiba INTERNATIONAL JOURNAL OF HEMATOLOGY
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
- (2016) Rishi G. Vaswani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent Progress in Histone Demethylase Inhibitors
- (2016) Tom E. McAllister et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1
- (2016) Jacob I Stuckey et al. Nature Chemical Biology
- Design and characterization of bivalent BET inhibitors
- (2016) Minoru Tanaka et al. Nature Chemical Biology
- An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
- (2016) Maia Vinogradova et al. Nature Chemical Biology
- The molecular hallmarks of epigenetic control
- (2016) C. David Allis et al. NATURE REVIEWS GENETICS
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain
- (2016) Paul Bamborough et al. ACS Medicinal Chemistry Letters
- Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7
- (2016) Chunyan Ren et al. ACS Medicinal Chemistry Letters
- Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
- (2016) M. W. M. Ku hn et al. Cancer Discovery
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Protein arginine methylation/demethylation and cancer
- (2016) Coralie Poulard et al. Oncotarget
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- Histone Lysine Demethylase Inhibitors
- (2016) Ashwini Jambhekar et al. Cold Spring Harbor Perspectives in Medicine
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
- (2015) Peter G. K. Clark et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
- (2015) Michael Lübbert et al. ANNALS OF HEMATOLOGY
- A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
- (2015) Helai P. Mohammad et al. CANCER CELL
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
- (2015) David Roulois et al. CELL
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes
- (2015) Lingling Duan et al. CHEMISTRY & BIOLOGY
- A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
- (2015) A. M. Evens et al. CLINICAL CANCER RESEARCH
- DNA hypomethylation-mediated activation ofCancer/Testis Antigen 45(CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer
- (2015) Wa Zhang et al. Epigenetics
- Open access chemical probes for epigenetic targets
- (2015) Peter J Brown et al. Future Medicinal Chemistry
- The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains
- (2015) Artyom A. Alekseyenko et al. GENES & DEVELOPMENT
- A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
- (2015) B. J. Eigl et al. INVESTIGATIONAL NEW DRUGS
- Efficacy of Tranylcypromine in Bipolar Depression
- (2015) Willemijn T. Heijnen et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B
- (2015) Peiling Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- 9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain
- (2015) Sarah Picaud et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
- (2015) Ludovic Drouin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition
- (2015) Natalie H. Theodoulou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor
- (2015) Wylie S. Palmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Integrative analysis of haplotype-resolved epigenomes across human tissues
- (2015) Danny Leung et al. NATURE
- SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
- (2015) Kimberly H Kim et al. NATURE MEDICINE
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion
- (2015) Xiang-Ping Yang et al. Scientific Reports
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance
- (2015) O. Fedorov et al. Science Advances
- The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia
- (2015) William N. Pappano et al. PLoS One
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers
- (2014) David A. Russler-Germain et al. CANCER CELL
- An epigenomic approach to therapy for tamoxifen-resistant breast cancer
- (2014) Qin Feng et al. CELL RESEARCH
- Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
- (2014) S. Sankar et al. CLINICAL CANCER RESEARCH
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date
- (2014) Daniel P. Mould et al. MEDICINAL RESEARCH REVIEWS
- Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation
- (2014) B. G. Wilson et al. MOLECULAR AND CELLULAR BIOLOGY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
- (2014) M. L. Guzman et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of demethylases by GSK-J1/J4
- (2014) Bo Heinemann et al. NATURE
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors
- (2014) William Lee et al. NATURE GENETICS
- ARID1B is a specific vulnerability in ARID1A-mutant cancers
- (2014) Katherine C Helming et al. NATURE MEDICINE
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain
- (2014) Emmanuel H. Demont et al. ACS Medicinal Chemistry Letters
- Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2014) P Tan et al. Blood Cancer Journal
- Bromodomain Protein BRD4 Is Required for Estrogen Receptor-Dependent Enhancer Activation and Gene Transcription
- (2014) Sankari Nagarajan et al. Cell Reports
- Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
- (2013) Mathew P. Martin et al. ACS Chemical Biology
- Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas
- (2013) Adam M. Fontebasso et al. ACTA NEUROPATHOLOGICA
- The Rac activator DOCK2 regulates natural killer cell-mediated cytotoxicity in mice through the lytic synapse formation
- (2013) Y. Sakai et al. BLOOD
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
- (2013) S. R. Daigle et al. BLOOD
- EZH2 mutations are frequent and represent an early event in follicular lymphoma
- (2013) C. Bodor et al. BLOOD
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
- (2013) A. T. Brunetto et al. CLINICAL CANCER RESEARCH
- Induction of sarcomas by mutant IDH2
- (2013) C. Lu et al. GENES & DEVELOPMENT
- Small-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3
- (2013) Lindsey I. James et al. JOURNAL OF MEDICINAL CHEMISTRY
- High-Throughput Virtual Screening Identifies Novel N′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors
- (2013) Venkataswamy Sorna et al. JOURNAL OF MEDICINAL CHEMISTRY
- NUT Midline Carcinoma: An Aggressive Intrathoracic Neoplasm
- (2013) Sameer A. Parikh et al. Journal of Thoracic Oncology
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain
- (2013) Lindsey I James et al. Nature Chemical Biology
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
- (2013) A. Hunter Shain et al. PLoS One
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma
- (2012) Yuan Yuan et al. ACS Chemical Biology
- Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma
- (2012) Adrian M. Dubuc et al. ACTA NEUROPATHOLOGICA
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
- (2012) William J. Harris et al. CANCER CELL
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- The Origin and Evolution of Mutations in Acute Myeloid Leukemia
- (2012) John S. Welch et al. CELL
- Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
- (2012) C. Qian et al. CLINICAL CANCER RESEARCH
- SPINDLIN1 Promotes Cancer Cell Proliferation through Activation of WNT/TCF-4 Signaling
- (2012) J.-X. Wang et al. MOLECULAR CANCER RESEARCH
- Dissecting the genomic complexity underlying medulloblastoma
- (2012) David T. W. Jones et al. NATURE
- A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
- (2012) Laurens Kruidenier et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes
- (2012) Matthieu Le Gallo et al. NATURE GENETICS
- Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes
- (2012) Zhi Jiang Zang et al. NATURE GENETICS
- Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
- (2012) Tino Schenk et al. NATURE MEDICINE
- Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
- (2012) Li Shen et al. PLoS One
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
- (2011) Bin Guan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes
- (2011) Jagat C. Borah et al. CHEMISTRY & BIOLOGY
- The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
- (2011) Rasheduzzaman Chowdhury et al. EMBO REPORTS
- Entinostat for treatment of solid tumors and hematologic malignancies
- (2011) Jeffrey Knipstein et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
- (2011) Tim J. Wigle et al. FEBS LETTERS
- Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer
- (2011) J. H. Kim et al. GENOME RESEARCH
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
- (2011) Alex J. Kuo et al. MOLECULAR CELL
- Unknown
- (2011) Antonio Furlan et al. MOLECULAR MEDICINE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
- (2011) Ignacio Varela et al. NATURE
- A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
- (2011) Masoud Vedadi et al. Nature Chemical Biology
- Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
- (2011) Yaoting Gui et al. NATURE GENETICS
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera
- (2010) F. Perna et al. BLOOD
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
- (2010) Gorica Nikoloski et al. NATURE GENETICS
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
- (2010) Thomas Ernst et al. NATURE GENETICS
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- Polycomb CBX7 Promotes Initiation of Heritable Repression of Genes Frequently Silenced with Cancer-Specific DNA Hypermethylation
- (2009) H. P. Mohammad et al. CANCER RESEARCH
- Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
- (2009) D. J. Stewart et al. CLINICAL CANCER RESEARCH
- Targeting DNA Methylation
- (2009) J.-P. J. Issa et al. CLINICAL CANCER RESEARCH
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
- (2009) Gijs van Haaften et al. NATURE GENETICS
- Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294
- (2009) Yanqi Chang et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha
- (2008) Luigi Scotto et al. Molecular Cancer
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now